Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A systematic review analyses the results of 177 trials conducted between 1982 and 2016, including 18,436 patients who underwent electrocardiographic evaluation during malaria clinical trials. Nick White and colleagues found that serious cardiovascular side effects, which include sudden cardiac death, are very rare in the treatment of malaria with quinoline antimalarials. The work emphasises the importance of continued pharmacovigilance with the increasing use of quinoline antimalarials in mass treatment strategies such as intermittent preventative treatment and mass drug administration.

Stethoscope

Similar stories

Real-time genetic surveillance can support timely, evidence-based responses to shifting malaria threats

A sharp decline in piperaquine-resistant strains of P. Falciparum malaria following drug policy revisions across the Greater Mekong Subregion (GMS) highlights how real-time genetic data can support timely, evidence-based responses to shifting malaria threats, say researchers in a study published in Nature Communications.